Fatty acid metabolism and drug resistance to EZH2 inhibition.
作者信息
Wang Yemin
机构信息
Department of Pathology and Laboratory Medicine, University of British Columbia, 236-2660 Oak Street, Vancouver, BC V6H 3Z6, Canada; Department of Molecular Oncology, British Columbia Cancer Research Institute, Vancouver, BC, Canada.
出版信息
EBioMedicine. 2022 Mar;77:103916. doi: 10.1016/j.ebiom.2022.103916. Epub 2022 Mar 3.
Abstract
摘要
相似文献
1
Fatty acid metabolism and drug resistance to EZH2 inhibition.脂肪酸代谢与对EZH2抑制的耐药性。
EBioMedicine. 2022 Mar;77:103916. doi: 10.1016/j.ebiom.2022.103916. Epub 2022 Mar 3.
2
Enhancer of zeste homolog 2 promotes cisplatin resistance by reducing cellular platinum accumulation.增强子结合锌指蛋白 2 通过减少细胞内铂蓄积促进顺铂耐药。
Cancer Sci. 2018 Jun;109(6):1853-1864. doi: 10.1111/cas.13599. Epub 2018 May 15.
3
lncRNA TUG1 inhibits the cancer stem cell‑like properties of temozolomide‑resistant glioma cells by interacting with EZH2.长链非编码 RNA TUG1 通过与 EZH2 相互作用抑制替莫唑胺耐药脑胶质瘤细胞的肿瘤干细胞样特性。
Mol Med Rep. 2021 Jul;24(1). doi: 10.3892/mmr.2021.12172. Epub 2021 May 26.
4
Inhibition of enhancer of zeste homolog 2 (EZH2) overcomes enzalutamide resistance in castration-resistant prostate cancer.抑制增强子的外显子 2（EZH2）可克服去势抵抗性前列腺癌对恩杂鲁胺的耐药性。
J Biol Chem. 2019 Jun 21;294(25):9911-9923. doi: 10.1074/jbc.RA119.008152. Epub 2019 May 13.
5
EZH2 inhibition sensitizes tamoxifen‑resistant breast cancer cells through cell cycle regulation.EZH2 抑制通过细胞周期调控使他莫昔芬耐药的乳腺癌细胞敏感。
Mol Med Rep. 2018 Feb;17(2):2642-2650. doi: 10.3892/mmr.2017.8160. Epub 2017 Nov 27.
6
Loss of the histone methyltransferase EZH2 induces resistance to multiple drugs in acute myeloid leukemia.组蛋白甲基转移酶EZH2的缺失会诱导急性髓系白血病对多种药物产生耐药性。
Nat Med. 2017 Jan;23(1):69-78. doi: 10.1038/nm.4247. Epub 2016 Dec 12.
7
Mechanisms of resistance to EZH2 inhibitors in diffuse large B-cell lymphomas.EZH2 抑制剂在弥漫性大 B 细胞淋巴瘤中的耐药机制。
Blood. 2018 May 10;131(19):2125-2137. doi: 10.1182/blood-2017-08-804344. Epub 2018 Mar 23.
8
SWI/SNF catalytic subunits' switch drives resistance to EZH2 inhibitors in ARID1A-mutated cells.SWI/SNF 催化亚基的开关驱动 ARID1A 突变细胞对 EZH2 抑制剂的耐药性。
Nat Commun. 2018 Oct 8;9(1):4116. doi: 10.1038/s41467-018-06656-6.
9
Enhancer of zeste homolog 2 promotes hepatocellular cancer progression and chemoresistance by enhancing protein kinase B activation through microRNA-381-mediated SET domain bifurcated 1.增强子结合蛋白 EZH2 通过 microRNA-381 介导的 SET 结构域分叉蛋白 1 促进蛋白激酶 B 的激活，从而促进肝癌的进展和化疗耐药性。
Bioengineered. 2022 Mar;13(3):5737-5755. doi: 10.1080/21655979.2021.2023792.
10
Oncogenic enhancer of zeste homolog 2 is an actionable target in patients with non-small cell lung cancer.EZH2 是治疗非小细胞肺癌的潜在靶点。
Cancer Med. 2019 Oct;8(14):6383-6392. doi: 10.1002/cam4.1855. Epub 2019 Aug 27.
引用本文的文献
1
A targetable antioxidant defense mechanism to EZH2 inhibitors enhances tumor cell vulnerability to ferroptosis.一种针对EZH2抑制剂的可靶向抗氧化防御机制增强了肿瘤细胞对铁死亡的易感性。
Cell Death Dis. 2025 Apr 14;16(1):291. doi: 10.1038/s41419-025-07607-y.
2
Spatiotemporal evolutionary process of osteosarcoma immune microenvironment remodeling and C1QBP-driven drug resistance deciphered through single-cell multi-dimensional analysis.通过单细胞多维度分析解析骨肉瘤免疫微环境重塑和C1QBP驱动的耐药性的时空进化过程。
Bioeng Transl Med. 2024 Apr 10;9(5):e10654. doi: 10.1002/btm2.10654. eCollection 2024 Sep.
3
Development of fatty acid metabolism score based on gene signature for predicting prognosis and immunotherapy response in colon cancer.基于基因特征的脂肪酸代谢评分在预测结肠癌预后和免疫治疗反应中的研究。
Clin Transl Oncol. 2024 Mar;26(3):630-643. doi: 10.1007/s12094-023-03282-7. Epub 2023 Jul 22.
Zotero 插件